Table. Efficacy of abemaciclib in HR+/HER2– advanced breast cancer.
| Trial | Daily treatment | No. of patients | ORR | Median progression-free survival | Median overall survival |
|---|---|---|---|---|---|
| MONARCH 11 | abemaciclib monotherapy | 132 | 19.7% | 6 months | 17.7 months |
| MONARCH 22,3 | abemaciclib + fulvestrant | 446 | 35.2% | 16.4 months | 46.7 months |
| placebo + fulvestrant | 223 | 16.1% | 9.3 months | 37.3 months | |
| MONARCH 34 | abemaciclib + aromatase inhibitor* | 326 | 48.2.% | 28.2 months | – |
| placebo + aromatase inhibitor* | 162 | 34.5% | 14.7 months | – |
* anastrozole or letrozole
HR+ hormone receptor positive
HER2– human epidermal growth factor receptor 2 negative
ORR objective response rate estimated as the total number of complete and partial responses divided by the number of patients